Odabas, H. Et Al. 2011. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment. Journal of B.U.ON. , vol.16, no.3 , 460-463.

Odabas, H., Ozdemir, N., Isik, M., Abali, H., Oksuzoglu, B., Kos, T., ... Civelek, B.(2011). Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment. Journal of B.U.ON. , vol.16, no.3, 460-463.

Odabas, H. Et Al. "Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment," Journal of B.U.ON. , vol.16, no.3, 460-463, 2011

Odabas, H. Et Al. "Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment." Journal of B.U.ON. , vol.16, no.3, pp.460-463, 2011

Odabas, H. Et Al. (2011) . "Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment." Journal of B.U.ON. , vol.16, no.3, pp.460-463.

@article{article, author={H. Odabas Et Al. }, title={Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment}, journal={Journal of B.U.ON.}, year=2011, pages={460-463} }